
Precise Bio: Innovating in regenerative medicine through 4D bio-fabrication of tissues and organs.
Founded with a mission to revolutionize regenerative medicine, Precise Bio focuses on developing and commercializing 4D bio-fabricated functional tissues and organs. The company leverages an integrated 3D printing and tissue-engineering platform to produce scalable, repeatable bio-fabricated organs from patients' own cells. Their core vision is to put advanced tissue engineering science into the hands of clinicians, aiming to significantly improve patient outcomes and the quality of healthcare.
Notable figures affiliated with Precise Bio include leading experts in tissue engineering and regenerative medicine. The company has attracted significant investment from prominent venture capital firms specializing in biotech innovations. Key achievements include the successful development of their 4D printing platform and the creation of functional bio-fabricated tissues that have shown promising results in preclinical trials. Overall, Precise Bio's impact lies in its potential to transform organ transplantation and regenerative therapies, offering new hope for patients with organ failure and other critical conditions.

3DBio
3dbiocorp.com

Systemic Bio
systemic.bio

VivoSim Labs
organovo.com

A.d.a.m.

3D Biotek
3dbiotek.com

FluidForm
fluidformbio.com

Restor3d
restor3d.com

SunP Biotech
sunpbiotech.com

Ortuvo

Trestle Biotherapeutics
trestlebio.com

Frontier Bio
frontierbio.com

Gel4Med
gelformed.com

Regenevida
recombinetics.com

Satellite Bio
satellite.bio

LyGenesis
lygenesis.com
Companies similar to Precise Bio include 3DBio, Systemic Bio, VivoSim Labs and A.d.a.m..
Precise Bio was founded in 2015.
Precise Bio's headquarters is located in Winston-Salem, NC, US.
Precise Bio's most recent funding round was for $12M (USD) in July 2022.
As of Jul 18, 2022, Precise Bio has disclosed funding of $27.5M (USD). Undisclosed round amounts are excluded.
Precise Bio has 33 employees as of Feb 5, 2024.